Lonza to Produce Aruvant’s ARU-1801 for Pivotal Trial

Lonza to Produce Aruvant’s ARU-1801 for Pivotal Trial

284971

Lonza to Produce Aruvant’s ARU-1801 for Pivotal Trial

A recent manufacturing agreement between Aruvant Sciences and Lonza will advance the development of ARU-1801, an investigational gene therapy for the treatment of sickle cell disease (SCD). Under the agreement, Lonza will be responsible for producing Aruvant’s gene therapy for an upcoming pivotal clinical trial. The company already has begun transferring manufacturing activities to establish a robust production of ARU-1801. Once the process is complete, the treatment will be produced under current Good Manufacturing Practices — standards set…

You must be logged in to read/download the full post.